AstraZeneca's Indian unit is planning to sell its 64-acre manufacturing facility in North Bengaluru for an estimated ₹3,400 crore. The move is part of a global review of its manufacturing network and a broader land monetization strategy. Developers like Sattva Group, Aurobindo Pharma, and RMZ have shown interest in the prime land parcel.
Source link
AstraZeneca India plans to sell 64-acre Bengaluru site for ₹3,400 crore
